| NCT06664853 | Open-Label Extension of EryDex Study IEDAT-04-2022 | RECRUITING | PHASE3 | 2024-12-11 | 2026-11-30 | 2026-11-30 |
| NCT06193200 | Evaluate the Neurological Effects of EryDex on Subjects With A-T | ACTIVE_NOT_RECRUITING | PHASE3 | 2024-06-24 | 2025-12 | 2025-12 |
| NCT03563053 | Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study | TERMINATED | PHASE3 | 2018-06-12 | 2022-09-02 | 2022-09-02 |
| NCT02770807 | Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients | COMPLETED | PHASE3 | 2017-03-02 | 2021-05-13 | 2021-05-13 |
| NCT02380924 | Recovery and Survival of EryDex in Non-patient Volunteers | COMPLETED | PHASE1 | 2015-01 | 2015-06 | 2015-06 |
| NCT01925859 | EryDex Pharmacokinetics in Healthy Volunteers | COMPLETED | PHASE1 | 2013-06 | 2013-10 | 2013-10 |
| NCT01255358 | Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Teleangiectasia Patients | COMPLETED | PHASE2 | 2011-02 | 2011-12 | 2011-09 |
| NCT01277289 | Intra-erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-dependent Crohn's Disease | TERMINATED | PHASE3 | 2009-06-03 | 2012-06 | 2011-12-30 |
| NCT01171807 | Erythrocytes-Mediated Delivery Of Dexamethasone 21-Phosphate In Steroid-Dependent Ulcerative Colitis | COMPLETED | PHASE2 | 2003-07-22 | 2007-05-15 | 2007-05-15 |